Anti-ganglioside antibodies and clinical outcome of patients with Guillain–Barré Syndrome in northeast Brazil
Abstract:Dourado ME, Duarte RC, Ferreira LC, Queiroz JW, Illa I, Perez-Perez G, Guerrant RL, Jerônimo SMB. Anti-ganglioside antibodies and clinical outcome of patients with Guillain–Barré Syndrome in northeast Brazil.
Acta Neurol Scand 2003: 108: 102–108. © Blackwell Munksgaard 2003. Objectives –
The goal of this study was to investigate the frequency of GM1 antibodies and to assess whether exposure to Campylobacter jejuni was associated with a distinct clinical variant of Guillain–Barré Syndrome (GBS) or disease outcome in Rio Grande do Norte, Brazil. Material and methods –
Forty-one patients with a presumed diagnosis of GBS were enrolled and prospectively studied between June 1994 and November 1999. Results –
Anti-GM1 was present in 51.2% (n = 21) of patients. The presence of anti-GM1 was significantly associated with acute axonal motor neuropathy when compared to acute inflammatory demyelinating polyneuropathy (P = 0.01). Patients with anti-GM1 antibodies presented distal muscle involvement and fewer sensory deficits. Age, time to nadir and ventilatory assistance were not associated with anti-GM1 antibodies. Eight out of 21 patients (32%) presented with anti-C. jejuni antibodies. Clinical features were similar for patients with GBS with positive and negative C. jejuni antibodies. Anti-GM1 antibodies were associated with C. jejuni infection (P = 0.0005). Presence of anti-GM1 and C. jejuni antibodies did not indicate a worse prognosis. Conclusion –
Patients with GBS and anti-GM1 antibodies had more distal muscle weakness, fewer sensory deficits, more axonal degeneration and C. jejuni infection, but these findings were not associated with a worse prognosis.
Document Type: Research Article
Affiliations: 1: Departamento de Bioquímica, Centro de Biociências, 2: Department of Neurology, University of Barcelona, Barcelona, Spain; 3: Department of Medicine and Microbiology, New York University School of Medicine, New York, NY; 4: Department of Medicine, University of Virginia, Charlottesville, VA, USA
Publication date: August 1, 2003